Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
10.4048/jbc.2016.19.3.261
- Author:
Yoon Yang JUNG
1
;
Chang Lim HYUN
;
Min Sun JIN
;
In Ae PARK
;
Yul Ri CHUNG
;
Bobae SHIM
;
Kyu Ho LEE
;
Han Suk RYU
Author Information
1. Department of Pathology, Myongji Hospital, Goyang, Korea.
- Publication Type:Original Article
- Keywords:
Core needle biopsy;
Neoadjuvant therapy;
Treatment outcome;
Triple-negative breast neoplasms
- MeSH:
Area Under Curve;
Biopsy, Large-Core Needle;
Chemotherapy, Adjuvant;
Cyclophosphamide;
Cytoplasm;
Doxorubicin;
Drug Therapy*;
Humans;
Lymphocytes, Tumor-Infiltrating;
Necrosis;
Neoadjuvant Therapy;
ROC Curve;
Treatment Outcome;
Triple Negative Breast Neoplasms*
- From:Journal of Breast Cancer
2016;19(3):261-267
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: There is no standard targeted therapy for the treatment of triple-negative breast cancer (TNBC). Therefore, its management heavily depends on adjuvant chemotherapy. Using core needle biopsy, this study evaluated the histological factors of TNBC predicting the response to chemotherapy. METHODS: One hundred forty-three TNBC patients who received single-regimen neoadjuvant chemotherapy (NAC) with the combination of doxorubicin, cyclophosphamide, and docetaxel were enrolled. The core needle biopsy specimens acquired before NAC were used to analyze the clinicopathologic variables and overall performance of the predictive model for therapeutic response. RESULTS: Independent predictors of pathologic complete response after NAC were found to be higher number of tumor infiltrating lymphocytes (p=0.007), absence of clear cytoplasm (p=0.008), low necrosis (p=0.018), and high histologic grade (p=0.039). In the receiver operating characteristics curve analysis, the area under curve for the combination of these four variables was 0.777. CONCLUSION: The present study demonstrated that a predictive model using the above four variables can predict therapeutic response to single-regimen NAC with the combination of doxorubicin, cyclophosphamide, and docetaxel in TNBC. Therefore, adding these morphologic variables to clinical and genomic signatures might enhance the ability to predict the therapeutic response to NAC in TNBC.
